메뉴 건너뛰기




Volumn 48, Issue 4, 2009, Pages 332-341

Update on immunotherapy for systemic lupus erythematosus - What's hot and what's not!

Author keywords

Autoimmune; Immunosuppressive; Mycophenolate; Nephritis; Rituximab

Indexed keywords

ABATACEPT; ABETIMUS; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; BG 9588; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY COMPLEMENT COMPONENT C5; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCREZULIMAB; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

EID: 63249098535     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken476     Document Type: Review
Times cited : (57)

References (96)
  • 1
    • 4043179907 scopus 로고    scopus 로고
    • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
    • Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
    • (2004) Arthritis Rheum , vol.50 , pp. 2580-2589
    • Looney, R.J.1    Anolik, J.H.2    Campbell, D.3
  • 2
    • 0033883903 scopus 로고    scopus 로고
    • Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
    • Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
    • (2000) Arthritis Rheum , vol.43 , pp. 1790-1800
    • Llorente, L.1    Richaud-Patin, Y.2    Garcia-Padilla, C.3
  • 3
    • 0032728801 scopus 로고    scopus 로고
    • A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response
    • Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-12.
    • (1999) Lupus , vol.8 , pp. 705-712
    • Levy, Y.1    Sherer, Y.2    Ahmed, A.3
  • 4
    • 2942700114 scopus 로고    scopus 로고
    • Autologous stem cell transplantation for systemic lupus erythematosus
    • Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-76.
    • (2004) Lupus , vol.13 , pp. 168-176
    • Jayne, D.1    Passweg, J.2    Marmont, A.3
  • 5
    • 0032986483 scopus 로고    scopus 로고
    • Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
    • Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 1999;10:833-9.
    • (1999) J Am Soc Nephrol , vol.10 , pp. 833-839
    • Dooley, M.A.1    Cosio, F.G.2    Nachman, P.H.3
  • 6
    • 1642501086 scopus 로고    scopus 로고
    • The NIH pulse cyclophosphamide regime: The end of an era?
    • Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: The end of an era? Lupus 2004;13:1-3.
    • (2004) Lupus , vol.13 , pp. 1-3
    • Karim, Y.1    D'Cruz, D.P.2
  • 7
    • 0033979772 scopus 로고    scopus 로고
    • The evolving role of mycophenolate mofetil in renal transplantation
    • Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. Q J Med 2000;93:15-20.
    • (2000) Q J Med , vol.93 , pp. 15-20
    • Warrens, A.N.1
  • 8
    • 33144475027 scopus 로고    scopus 로고
    • Mycophenolate mofetil treatment of myasthenia gravis
    • Cahoon WD Jr, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother 2006;40:295-8.
    • (2006) Ann Pharmacother , vol.40 , pp. 295-298
    • Cahoon Jr, W.D.1    Kockler, D.R.2
  • 9
    • 0037825768 scopus 로고    scopus 로고
    • Mycophenolate mofetil (CellCept) for psoriasis: A two-center, prospective, open-label clinical trial
    • Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (CellCept) for psoriasis: A two-center, prospective, open-label clinical trial. J Cutan Med Surg 2003;7:193-7.
    • (2003) J Cutan Med Surg , vol.7 , pp. 193-197
    • Zhou, Y.1    Rosenthal, D.2    Dutz, J.3    Ho, V.4
  • 10
    • 0034045586 scopus 로고    scopus 로고
    • Mycophenolate mofetil and its mechanisms of action
    • Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
    • (2000) Immunopharmacology , vol.47 , pp. 85-118
    • Allison, A.C.1    Eugui, E.M.2
  • 11
    • 0035051925 scopus 로고    scopus 로고
    • Treatment of systemic lupus erythematosus with mycophenolate mofetil
    • Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10:203-8.
    • (2001) Lupus , vol.10 , pp. 203-208
    • Adu, D.1    Cross, J.2    Jayne, D.R.3
  • 12
    • 0036673864 scopus 로고    scopus 로고
    • Immunosuppressive therapy in lupus nephritis: The Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
    • Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: The Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46: 2121-31.
    • (2002) Arthritis Rheum , vol.46 , pp. 2121-2131
    • Houssiau, F.A.1    Vasconcelos, C.2    D'Cruz, D.3
  • 13
    • 28144433147 scopus 로고    scopus 로고
    • Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    • Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
    • (2005) N Engl J Med , vol.353 , pp. 2219-2228
    • Ginzler, E.M.1    Dooley, M.A.2    Aranow, C.3
  • 14
    • 63249110405 scopus 로고    scopus 로고
    • Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by racial group (abstract)
    • Ginzler EM, Appel GB, Dooley MA et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by racial group (abstract). Rheumatology 2007;56:4308.
    • (2007) Rheumatology , vol.56 , pp. 4308
    • Ginzler, E.M.1    Appel, G.B.2    Dooley, M.A.3
  • 15
    • 20444466207 scopus 로고    scopus 로고
    • Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
    • Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16: 1076-84.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1076-1084
    • Chan, T.M.1    Tse, K.C.2    Tang, C.S.3    Mok, M.Y.4    Li, F.K.5
  • 16
    • 1442355581 scopus 로고    scopus 로고
    • Sequential therapies for proliferative lupus nephritis
    • Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
    • (2004) N Engl J Med , vol.350 , pp. 971-980
    • Contreras, G.1    Pardo, V.2    Leclercq, B.3
  • 17
    • 33745243801 scopus 로고    scopus 로고
    • Anti-inflammatory and immuno-suppressive drugs and reproduction
    • Østensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immuno-suppressive drugs and reproduction. Arthritis Res Ther 2006;8:209.
    • (2006) Arthritis Res Ther , vol.8 , pp. 209
    • Østensen, M.1    Khamashta, M.2    Lockshin, M.3
  • 18
    • 2542469031 scopus 로고    scopus 로고
    • Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations
    • Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 2004;103:1091-4.
    • (2004) Obstet Gynecol , vol.103 , pp. 1091-1094
    • Le Ray, C.1    Coulomb, A.2    Elefant, E.3    Frydman, R.4    Audibert, F.5
  • 19
    • 20444494317 scopus 로고    scopus 로고
    • Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients
    • Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients. J Rheumatol 2005;32: 1047-52.
    • (2005) J Rheumatol , vol.32 , pp. 1047-1052
    • Pisoni, C.N.1    Sanchez, F.J.2    Karim, Y.3
  • 20
    • 0041464661 scopus 로고    scopus 로고
    • Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil
    • Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil. Lupus 2003; 12:630-2.
    • (2003) Lupus , vol.12 , pp. 630-632
    • Vasoo, S.1    Thumboo, J.2    Fong, K.Y.3
  • 21
    • 27744462578 scopus 로고    scopus 로고
    • Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus
    • Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005;14:856-8.
    • (2005) Lupus , vol.14 , pp. 856-858
    • Mak, A.1    Mok, C.C.2
  • 22
    • 0036785351 scopus 로고    scopus 로고
    • Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
    • Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
    • (2002) Ann Rheum Dis , vol.61 , pp. 883-888
    • Leandro, M.J.1    Edwards, J.C.2    Cambridge, G.3
  • 23
    • 0032769336 scopus 로고    scopus 로고
    • The central and multiple roles of B cells in lupus pathogenesis
    • Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169:107-21.
    • (1999) Immunol Rev , vol.169 , pp. 107-121
    • Chan, O.T.1    Madaio, M.P.2    Shlomchik, M.J.3
  • 24
    • 33847068351 scopus 로고    scopus 로고
    • Drug insight: The mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis
    • Taylor RP, Lindorfer MA. Drug insight: The mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
    • (2007) Nat Clin Pract Rheumatol , vol.3 , pp. 86-95
    • Taylor, R.P.1    Lindorfer, M.A.2
  • 26
    • 0036177919 scopus 로고    scopus 로고
    • Rituximab: Mechanism of action and resistance
    • Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl. 2):2-9.
    • (2002) Semin Oncol , vol.29 , Issue.1 SUPPL. 2 , pp. 2-9
    • Maloney, D.G.1    Smith, B.2    Rose, A.3
  • 27
    • 28544449032 scopus 로고    scopus 로고
    • B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients
    • Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
    • (2005) Rheumatology , vol.44 , pp. 1542-1545
    • Leandro, M.J.1    Cambridge, G.2    Edwards, J.C.3    Ehrenstein, M.R.4    Isenberg, D.A.5
  • 28
    • 4043179907 scopus 로고    scopus 로고
    • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
    • Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
    • (2004) Arthritis Rheum , vol.50 , pp. 2580-2589
    • Looney, R.J.1    Anolik, J.H.2    Campbell, D.3
  • 29
    • 70350525210 scopus 로고    scopus 로고
    • Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study
    • Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006;8:R83.
    • (2006) Arthritis Res Ther , vol.8
    • Vigna-Perez, M.1    Hernandez-Castro, B.2    Paredes-Saharopulos, O.3
  • 30
    • 13444252282 scopus 로고    scopus 로고
    • Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand
    • Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 2005;52:501-13.
    • (2005) Arthritis Rheum , vol.52 , pp. 501-513
    • Sfikakis, P.P.1    Boletis, J.N.2    Lionaki, S.3
  • 31
    • 34247246405 scopus 로고    scopus 로고
    • Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
    • Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72.
    • (2007) Arthritis Rheum , vol.56 , pp. 1263-1272
    • Gunnarsson, I.1    Sundelin, B.2    Jónsdóttir, T.3    Jacobson, S.H.4    Henriksson, E.W.5    van Vollenhoven, R.F.6
  • 32
    • 34147193717 scopus 로고    scopus 로고
    • Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
    • Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5.
    • (2007) Ann Rheum Dis , vol.66 , pp. 470-475
    • Tokunaga, M.1    Saito, K.2    Kawabata, D.3
  • 33
    • 39549108298 scopus 로고    scopus 로고
    • Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response
    • Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4.
    • (2008) Ann Rheum Dis , vol.67 , pp. 330-334
    • Jónsdóttir, T.1    Gunnarsson, I.2    Risselada, A.3    Henriksson, E.W.4    Klareskog, L.5    van Vollenhoven, R.F.6
  • 35
    • 63249122739 scopus 로고    scopus 로고
    • Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis (abstract)
    • Sangle SR, Davies RJ, Aslam L et al. Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis (abstract). Rheumatology 2007;56:S215.
    • (2007) Rheumatology , vol.56
    • Sangle, S.R.1    Davies, R.J.2    Aslam, L.3
  • 36
    • 63249129834 scopus 로고    scopus 로고
    • Genentech and Biogen Idec. http://www.gene.com/gene/news/press-releases/ dis play.do?method=detail&id=11247 (19 December 2008, date last accessed).
    • Genentech and Biogen Idec. http://www.gene.com/gene/news/press-releases/ dis play.do?method=detail&id=11247 (19 December 2008, date last accessed).
  • 37
    • 34548151122 scopus 로고    scopus 로고
    • B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response
    • Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1259-1262
    • Ng, K.P.1    Cambridge, G.2    Leandro, M.J.3    Edwards, J.C.4    Ehrenstein, M.5    Isenberg, D.A.6
  • 39
    • 33845869839 scopus 로고    scopus 로고
    • Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
    • Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.
    • (2007) Clin Immunol , vol.122 , pp. 62-74
    • Vallerskog, T.1    Gunnarsson, I.2    Widhe, M.3
  • 40
    • 8444223507 scopus 로고    scopus 로고
    • Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    • Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50:3580-90.
    • (2004) Arthritis Rheum , vol.50 , pp. 3580-3590
    • Anolik, J.H.1    Barnard, J.2    Cappione, A.3
  • 41
    • 0037289807 scopus 로고    scopus 로고
    • The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    • Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
    • (2003) Arthritis Rheum , vol.48 , pp. 455-459
    • Anolik, J.H.1    Campbell, D.2    Felgar, R.E.3
  • 42
    • 0041571732 scopus 로고    scopus 로고
    • Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
    • Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-54.
    • (2003) Arthritis Rheum , vol.48 , pp. 2146-2154
    • Cambridge, G.1    Leandro, M.J.2    Edwards, J.C.3
  • 43
    • 33750964016 scopus 로고    scopus 로고
    • B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles
    • Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006;54:3612-22.
    • (2006) Arthritis Rheum , vol.54 , pp. 3612-3622
    • Cambridge, G.1    Leandro, M.J.2    Teodorescu, M.3
  • 44
    • 34547488545 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease
    • Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28.
    • (2007) Arthritis Rheum , vol.56 , pp. 2116-2128
    • Calabrese, L.H.1    Molloy, E.S.2    Huang, D.3    Ransohoff, R.M.4
  • 45
    • 63249084945 scopus 로고    scopus 로고
    • Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00626197?term=ocrelizumab&cond=lupus&rank=1 (19 December 2008, date last accessed).
    • Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00626197?term=ocrelizumab&cond=lupus&rank=1 (19 December 2008, date last accessed).
  • 46
    • 63249093130 scopus 로고    scopus 로고
    • Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00539838?term=ocrelizumab&cond=lupus&rank=2 (19 December 2008, date last accessed).
    • Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00539838?term=ocrelizumab&cond=lupus&rank=2 (19 December 2008, date last accessed).
  • 47
    • 53749095799 scopus 로고    scopus 로고
    • Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
    • Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
    • (2006) Arthritis Res Ther , vol.8
    • Dörner, T.1    Kaufmann, J.2    Wegener, W.A.3    Teoh, N.4    Goldenberg, D.M.5    Burmester, G.R.6
  • 48
    • 63249128038 scopus 로고    scopus 로고
    • UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00660881?term=epratuzumab&cond=lupus&rank=4 (19 December 2008, date last accessed).
    • UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00660881?term=epratuzumab&cond=lupus&rank=4 (19 December 2008, date last accessed).
  • 49
    • 63249133898 scopus 로고    scopus 로고
    • UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624351?term=epratuzumab&cond=lupus&rank=6 (19 December 2008, date last accessed).
    • UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624351?term=epratuzumab&cond=lupus&rank=6 (19 December 2008, date last accessed).
  • 50
    • 10744224617 scopus 로고    scopus 로고
    • B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations
    • Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86.
    • (2003) Arthritis Rheum , vol.48 , pp. 3475-3486
    • Stohl, W.1    Metyas, S.2    Tan, S.M.3
  • 51
    • 34548102544 scopus 로고    scopus 로고
    • Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial (abstract)
    • Furie R, Lisse J, Merrill JT et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial (abstract). Rheumatology 2006;54:S258.
    • (2006) Rheumatology , vol.54
    • Furie, R.1    Lisse, J.2    Merrill, J.T.3
  • 52
    • 34548542899 scopus 로고    scopus 로고
    • Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 Weeks (abstract)
    • Wallace DJ, Lisse J, Stohl W et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 Weeks (abstract). Rheumatology 2006;54:S790.
    • (2006) Rheumatology , vol.54
    • Wallace, D.J.1    Lisse, J.2    Stohl, W.3
  • 53
    • 63249120429 scopus 로고    scopus 로고
    • Human Genome Sciences. http://clinicaltrials.gov/ct2/show/NCT00410384 (19 December 2008, date last accessed).
    • Human Genome Sciences. http://clinicaltrials.gov/ct2/show/NCT00410384 (19 December 2008, date last accessed).
  • 54
    • 63249125886 scopus 로고    scopus 로고
    • Serum levels of TNF family members APRIL and BLyS are inversely correlated in SLE
    • Advance Access published August 2, doi: 10.1136/ard.2008.090928
    • Morel J, Roubille C, Planelles L et al. Serum levels of TNF family members APRIL and BLyS are inversely correlated in SLE. Ann Rheum Dis. Advance Access published August 2, 2008, doi: 10.1136/ard.2008.090928.
    • (2008) Ann Rheum Dis
    • Morel, J.1    Roubille, C.2    Planelles, L.3
  • 55
    • 63249117211 scopus 로고    scopus 로고
    • EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624338?term=atacicept&rank=3 (19 December 2008, date last accessed).
    • EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624338?term=atacicept&rank=3 (19 December 2008, date last accessed).
  • 56
    • 63249113118 scopus 로고    scopus 로고
    • EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show?term= atacicept&rank=6 (19 December 2008, date last accessed).
    • EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show?term= atacicept&rank=6 (19 December 2008, date last accessed).
  • 57
    • 2942703965 scopus 로고    scopus 로고
    • LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
    • Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004;13:323-27.
    • (2004) Lupus , vol.13 , pp. 323-327
    • Wallace, D.J.1    Tumlin, J.A.2
  • 58
    • 0037331980 scopus 로고    scopus 로고
    • LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study
    • Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
    • (2003) Arthritis Rheum , vol.48 , pp. 442-454
    • Alarcon-Segovia, D.1    Tumlin, J.A.2    Furie, R.A.3
  • 59
    • 0141849087 scopus 로고    scopus 로고
    • Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo
    • Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
    • (2003) Lupus , vol.12 , pp. 677-686
    • Strand, V.1    Aranow, C.2    Cardiel, M.H.3
  • 60
    • 49449093009 scopus 로고    scopus 로고
    • LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial
    • Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80.
    • (2008) Arthritis Rheum , vol.58 , pp. 2470-2480
    • Cardiel, M.H.1    Tumlin, J.A.2    Furie, R.A.3    Wallace, D.J.4    Joh, T.5    Linnik, M.D.6
  • 61
    • 63249107804 scopus 로고    scopus 로고
    • La Jolla Pharmaceutical Company; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00089804?term=LJP+394&rank=1 (19 December 2008, date last accessed).
    • La Jolla Pharmaceutical Company; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00089804?term=LJP+394&rank=1 (19 December 2008, date last accessed).
  • 62
    • 0033965079 scopus 로고    scopus 로고
    • Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
    • Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.
    • (2000) Nat Med , vol.6 , pp. 114
    • Kawai, T.1    Andrews, D.2    Colvin, R.B.3    Sachs, D.H.4    Cosimi, A.B.5
  • 63
    • 0038240916 scopus 로고    scopus 로고
    • Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE)
    • Davidson A, Wang X, Mihara M et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci 2003;987:188-98.
    • (2003) Ann N Y Acad Sci , vol.987 , pp. 188-198
    • Davidson, A.1    Wang, X.2    Mihara, M.3
  • 64
    • 0036272915 scopus 로고    scopus 로고
    • The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus
    • Huang W, Sinha J, Newman J et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46:1554-62.
    • (2002) Arthritis Rheum , vol.46 , pp. 1554-1562
    • Huang, W.1    Sinha, J.2    Newman, J.3
  • 65
    • 0030267659 scopus 로고    scopus 로고
    • Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response
    • Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
    • (1996) J Immunol , vol.157 , pp. 3159-3164
    • Early, G.S.1    Zhao, W.2    Burns, C.M.3
  • 66
    • 0037333857 scopus 로고    scopus 로고
    • A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
    • Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
    • (2003) Arthritis Rheum , vol.48 , pp. 719-727
    • Boumpas, D.T.1    Furie, R.2    Manzi, S.3
  • 67
    • 0036899589 scopus 로고    scopus 로고
    • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial
    • Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46: 3251-8.
    • (2002) Arthritis Rheum , vol.46 , pp. 3251-3258
    • Kalunian, K.C.1    Davis Jr, J.C.2    Merrill, J.T.3    Totoritis, M.C.4    Wofsy, D.5
  • 68
    • 0033932756 scopus 로고    scopus 로고
    • CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus
    • Mihara M, Tan I, Chuzhin Y et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
    • (2000) J Clin Invest , vol.106 , pp. 91-101
    • Mihara, M.1    Tan, I.2    Chuzhin, Y.3
  • 69
    • 0034605033 scopus 로고    scopus 로고
    • Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
    • Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
    • (2000) J Exp Med , vol.192 , pp. 681-694
    • Abrams, J.R.1    Kelley, S.L.2    Hayes, E.3
  • 70
    • 0033135564 scopus 로고    scopus 로고
    • CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
    • Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103: 1243-52.
    • (1999) J Clin Invest , vol.103 , pp. 1243-1252
    • Abrams, J.R.1    Lebwohl, M.G.2    Guzzo, C.A.3
  • 71
    • 0036275436 scopus 로고    scopus 로고
    • Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
    • Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
    • (2002) Arthritis Rheum , vol.46 , pp. 1470-1479
    • Moreland, L.W.1    Alten, R.2    Van den Bosch, F.3
  • 72
    • 0242574700 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    • Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
    • (2003) N Engl J Med , vol.349 , pp. 1907-1915
    • Kremer, J.M.1    Westhovens, R.2    Leon, M.3
  • 73
    • 0037868032 scopus 로고    scopus 로고
    • Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition
    • Schiffer L, Sinha J, Wang X et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171:489-97.
    • (2003) J Immunol , vol.171 , pp. 489-497
    • Schiffer, L.1    Sinha, J.2    Wang, X.3
  • 74
    • 0035284737 scopus 로고    scopus 로고
    • Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
    • Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6.
    • (2001) J Immunol , vol.166 , pp. 2913-2916
    • Daikh, D.I.1    Wofsy, D.2
  • 75
    • 63249088064 scopus 로고    scopus 로고
    • Bristol-Myers Squibb; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/ show/NCT00430677 (19 December 2008, date last accessed).
    • Bristol-Myers Squibb; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/ show/NCT00430677 (19 December 2008, date last accessed).
  • 76
    • 21744446004 scopus 로고    scopus 로고
    • Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey
    • De Bandt M, Sibilia J, Le Loë X et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 2005;7:R545-51.
    • (2005) Arthritis Res Ther , vol.7
    • De Bandt, M.1    Sibilia, J.2    Le Loë, X.3
  • 77
    • 34447505845 scopus 로고    scopus 로고
    • Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases
    • Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine 2007;86:242-51.
    • (2007) Medicine , vol.86 , pp. 242-251
    • Ramos-Casals, M.1    Brito-Zerón, P.2    Muñoz, S.3
  • 78
    • 0043175226 scopus 로고    scopus 로고
    • SLE - complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus
    • Aringer M, Smolen JS. SLE - complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003;5:172-7.
    • (2003) Arthritis Res Ther , vol.5 , pp. 172-177
    • Aringer, M.1    Smolen, J.S.2
  • 79
    • 5644258326 scopus 로고    scopus 로고
    • Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study
    • Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004;50:3161-9.
    • (2004) Arthritis Rheum , vol.50 , pp. 3161-3169
    • Aringer, M.1    Graninger, W.B.2    Steiner, G.3    Smolen, J.S.4
  • 81
    • 33646696885 scopus 로고    scopus 로고
    • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85. Erratum in: J Am Med Assoc 2006;295:2482.
    • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85. Erratum in: J Am Med Assoc 2006;295:2482.
  • 82
    • 67549117204 scopus 로고    scopus 로고
    • The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure adjusted pooled analyses of serious adverse events
    • Advance Access published August 27, doi:10.1136/ard.2008.091025
    • Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis. Advance Access published August 27, 2008, doi:10.1136/ard.2008.091025.
    • (2008) Ann Rheum Dis
    • Leombruno, J.P.1    Einarson, T.R.2    Keystone, E.C.3
  • 83
    • 33747008410 scopus 로고    scopus 로고
    • Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ. Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
    • Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ. Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
  • 84
    • 0029764359 scopus 로고    scopus 로고
    • Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
    • Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 8563-8568
    • Wang, Y.1    Hu, Q.2    Madri, J.A.3    Rollins, S.A.4    Chodera, A.5    Matis, L.A.6
  • 85
    • 2942716917 scopus 로고    scopus 로고
    • Inhibition of terminal complement: A novel therapeutic approach for the treatment of systemic lupus erythematosus
    • Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004;13:328-34.
    • (2004) Lupus , vol.13 , pp. 328-334
    • Rother, R.P.1    Mojcik, C.F.2    McCroskery, E.W.3
  • 86
    • 0036113782 scopus 로고    scopus 로고
    • The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases
    • Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-74.
    • (2002) Rheumatology , vol.41 , pp. 367-374
    • Pyne, D.1    Ehrenstein, M.2    Morris, V.3
  • 87
    • 0033554258 scopus 로고    scopus 로고
    • Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
    • Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354:569-70.
    • (1999) Lancet , vol.354 , pp. 569-570
    • Boletis, J.N.1    Ioannidis, J.P.2    Boki, K.A.3    Moutsopoulos, H.M.4
  • 88
    • 0034098474 scopus 로고    scopus 로고
    • Intravenous immunoglobulin treatment of lupus nephritis
    • Levy Y, Sherer Y, George J et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29:321-7.
    • (2000) Semin Arthritis Rheum , vol.29 , pp. 321-327
    • Levy, Y.1    Sherer, Y.2    George, J.3
  • 89
    • 10444255401 scopus 로고    scopus 로고
    • Intravenous immunoglobulin and the kidney-a two-edged sword
    • Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004;34:593-601.
    • (2004) Semin Arthritis Rheum , vol.34 , pp. 593-601
    • Orbach, H.1    Tishler, M.2    Shoenfeld, Y.3
  • 90
    • 0042667057 scopus 로고    scopus 로고
    • Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin
    • Brennan VM, Salomé-Bentley NJ, Chapel HM. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247-51.
    • (2003) Clin Exp Immunol , vol.133 , pp. 247-251
    • Brennan, V.M.1    Salomé-Bentley, N.J.2    Chapel, H.M.3
  • 91
    • 0027499768 scopus 로고
    • Apparent cure of rheumatoid arthritis by bone marrow transplantation
    • Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. Rheumatology 1993;20:137-40.
    • (1993) Rheumatology , vol.20 , pp. 137-140
    • Lowenthal, R.M.1    Cohen, M.L.2    Atkinson, K.3    Biggs, J.C.4
  • 92
    • 12144286975 scopus 로고    scopus 로고
    • Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR
    • Snowden JA, Passweg J, Moore JJ et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J Rheumatol 2004;31:482-8.
    • (2004) J Rheumatol , vol.31 , pp. 482-488
    • Snowden, J.A.1    Passweg, J.2    Moore, J.J.3
  • 93
    • 10744219522 scopus 로고    scopus 로고
    • High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus
    • Lisukov IA, Sizikova SA, Kulagin AD et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004;13:89-94.
    • (2004) Lupus , vol.13 , pp. 89-94
    • Lisukov, I.A.1    Sizikova, S.A.2    Kulagin, A.D.3
  • 94
    • 0036847280 scopus 로고    scopus 로고
    • Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients
    • Traynor AE, Barr WG, Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917-23.
    • (2002) Arthritis Rheum , vol.46 , pp. 2917-2923
    • Traynor, A.E.1    Barr, W.G.2    Rosa, R.M.3
  • 95
    • 0037235945 scopus 로고    scopus 로고
    • High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
    • Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48:166-73.
    • (2003) Arthritis Rheum , vol.48 , pp. 166-173
    • Petri, M.1    Jones, R.J.2    Brodsky, R.A.3
  • 96
    • 32044473487 scopus 로고    scopus 로고
    • Non myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus
    • Burt RK, Traynor A, Statkute L et al. Non myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. J Am Med Assoc 2006;295: 527-35.
    • (2006) J Am Med Assoc , vol.295 , pp. 527-535
    • Burt, R.K.1    Traynor, A.2    Statkute, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.